Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
IPO Year:
Exchange: AMEX
Website: stereotaxis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2024 | $5.00 | Buy | ROTH MKM |
| 7/12/2022 | $6.00 | Buy | Aegis Capital |
| 6/23/2022 | $6.00 | Buy | B. Riley Securities |
| 1/5/2022 | $11.00 | Buy | Craig-Hallum |
| 1/5/2022 | $13.00 | Buy | Loop Capital |
424B5 - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
10-Q - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
424B5 - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
SD - Stereotaxis, Inc. (0001289340) (Filer)
8-K - Stereotaxis, Inc. (0001289340) (Filer)
10-Q - Stereotaxis, Inc. (0001289340) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00
Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00
Craig-Hallum initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $11.00
Loop Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $13.00
Piper Sandler initiated coverage of Stereotaxis with a rating of Overweight and set a new price target of $9.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
4 - Stereotaxis, Inc. (0001289340) (Issuer)
Fastest customizable press release news feed in the world
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the world's first procedures using MAGiC Sweep™, the first and only robotically-navigated high-density electrophysiology (EP) mapping catheter. The procedures were performed by Dr. Raffaele Corbisiero and Dr. Pedram Kazemian at Deborah Heart and Lung Center in Browns Mills, New Jersey. "We're excited to be the first to demonstrate the value of robotic high-density mapping and to offer this important innovation to our patients," said Dr. Corbisiero, Chief of Electrophysiology at
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in New York City in September. H.C. Wainwright 27th Annual Global Investment ConferenceMr. Fischel will present an overview of Stereotaxis business on Wednesday, September 10th, 2025, at 8:00 am EDT and will be available that same day for one-on-one meetings. Lake Street Capital 9th Annual Best Ideas Growth ConferenceMr. Fischel will be available for one-on-one meetings on Thursday, September 11, 2025.
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. "We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption," said David Fischel, Chairman and CEO. "This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy." "Recent FDA clearance of MAGiC Sweep was a significant milestone a
ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world's first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia patients. High density mapping has transformed the EP field, enhancing cardiac ablation procedures by enabling more efficient, detailed and precise identification of a
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis second quarter 2025 financial results conference call When:Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (Interna
Led by Strategic Industry Partner and Select Institutional InvestorsProceeds Strengthen Balance Sheet and Support Commercialization of Innovation Strategy ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has entered into definitive agreements with investors for the sale of approximately $12.5 million of its shares of common stock in a registered direct offering, at a price per share of $2.00. The financing is being led by a strategic industry partner along with participation from a select group of institutional investors. "We appreciate the
ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. Titled "First In‑Human Results of the MAGiC Robotic Magnetic Navigation Radiofrequency Ablation Catheter," the publication is the first peer-reviewed literature supporting the efficacy and safety of Stereotaxis' MAGiC catheter. "We are delighted to see the strong efficacy and safety profile of MAGiC published in a prestigious journal," said David Fischel, Stereotaxis Chairman and
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) a
Live Leadership Updates
ST. LOUIS, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its technology will be featured during the upcoming HRX digital health conference taking place September 4-6, 2025, in Atlanta, Georgia. HRX, an initiative pioneered by the Heart Rhythm Society, is focused on exploring digital technologies that advance the frontiers of cardiovascular medicine. Stereotaxis CEO, David Fischel, will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Later that day, at 4:45 PM EDT, a distinguished panel of electrophysiologists, including Dr. Daniel Cooper,
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti
ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, the global leader and pioneer of robotic surgery. Dr. Curet joined Intuitive Surgical in 2005 and has since led the development of clinical evidence, physician education, and reimbursement and regulatory activities that have been instrumental to Intuitive Surgical's growth across multiple clinical specialties. For more than 20 years, Dr. Cu
Live finance-specific insights
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025. "We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption," said David Fischel, Chairman and CEO. "This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy." "Recent FDA clearance of MAGiC Sweep was a significant milestone a
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis second quarter 2025 financial results conference call When:Thursday, August 7, 2025, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (Interna
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) a
ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2024. "We have started a milestone rich year in which we will demonstrate the tangible reality of our overall strategic transformation into a company with an easily adopted robot that can navigate a proprietary set of catheters in EP and broadly across endovascular procedures," said David Fischel, Chairman and CEO. "Our progress leads to an expanded clinical impact, scalable capital model, strategic self-sufficiency, and an attractiv
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company's results and corporate developments. What:Stereotaxis fourth quarter and full year 2024 financial results conference call When:Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. "The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline," said David Fischel, Chairman and CEO. "We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company." "Revenue growth in the third quarter was driven by continued demand for Genesis with par
ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 third quarter on Monday, November 11, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What: Stereotaxis third quarter 2024 financial results conference call When: Monday, November 11, 2024, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963
ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2024. "We made significant progress over the last quarter on strategic innovation efforts that are establishing a solid foundation upon which to build a substantial and successful company," said David Fischel, Chairman and CEO. "Key milestones achieved include successfully obtaining CE mark in Europe and submitting a 510(k) application in the US for GenesisX, substantial progress with regulatory reviews of MAGiC in Europe and the US, and closing the acq
ST. LOUIS, July 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 second quarter on Monday, August 12, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis second quarter 2024 financial results conference call When:Monday, August 12, 2024, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (Interna
This live feed shows all institutional transactions in real time.
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)
SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)